| • | Aronson JK, Derry S, Loke YK.
Adverse drug reactions: keeping up to date.
Fundam Clin Pharmacol. 2002 Feb;16(1):49-56. Review.
| | • | Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH.
Timing of new black box warnings and withdrawals for prescription medications.
JAMA. 2002 May 1;287(17):2215-20.
| | • | Jonville-Bera AP, Giraudeau B, Blanc P, Beau-Salinas F, Autret-Leca E.
Frequency of adverse drug reactions in children: a prospective study.
Br J Clin Pharmacol. 2002 Feb;53(2):207-10.
| | • | Shojania KG, Duncan BW, McDonald KM, Wachter RM, Markowitz AJ.
Making health care safer: a critical analysis of patient safety practices.
Evid Rep Technol Assess ( Summ). 2001;(43): i-x, 1-668. Review.
| | • | Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J.
Analysis of the direct cost of adverse drug reactions in hospitalised patients.
Eur J Clin Pharmacol. 2001 Mar;56(12):935-41.
| | • | Ernst FR, Grizzle AJ.
Drug-related morbidity and mortality: updating the cost-of-illness model.
J Am Pharm Assoc ( Wash). 2001 Mar-Apr;41(2):192-9.
| | • | Bates DW.
Costs of drug-related morbidity and mortality: enormous and growing rapidly.
J Am Pharm Assoc ( Wash). 2001 Mar-Apr;41(2):156-7. No abstract available.
| | • | Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, Hurley J, Grad R, Latimer E, Perreault R, McLeod P, Huang A, Larochelle P, Mallet L.
Adverse events associated with prescription drug cost-sharing among poor and elderly persons.
JAMA. 2001 Jan 24-31;285(4):421-9.
| | • | Bond CA, Raehl CL, Franke T.
Interrelationships among mortality rates, drug costs, total cost of care, and length of stay in United States hospitals: summary and recommendations for clinical pharmacy services and staffing.
Pharmacotherapy. 2001 Feb;21(2):129-41.
| | • | Hanlon JT, Shimp LA, Semla TP.
Recent advances in geriatrics: drug-related problems in the elderly.
Ann Pharmacother. 2000 Mar;34(3):360-5. Review.
| | • | White TJ, Arakelian A, Rho JP.
Counting the costs of drug-related adverse events.
Pharmacoeconomics. 1999 May;15(5):445-58. Review.
| | • | Green CF, Mottram DR, Pirmohamed M, Horner R, Rowe PH.
Communication regarding adverse drug reactions between secondary and primary care: a postal questionnaire survey of general practitioners.
J Clin Pharm Ther. 1999 Apr;24(2):133-9.
| | • | Aparasu RR.
Visits to office-based physicians in the United States for medication-related morbidity.
J Am Pharm Assoc ( Wash). 1999 May-Jun;39(3):332-7.
| | • | Moore N, Lecointre D, Noblet C, Mabille M.
Frequency and cost of serious adverse drug reactions in a department of general medicine.
Br J Clin Pharmacol. 1998 Mar;45(3):301-8.
| | • | Holland EG, Degruy FV.
Drug-induced disorders.
Am Fam Physician. 1997 Nov 1;56(7):1781-8, 1791-2. Review.
| | • | Bootman JL, Harrison DL, Cox E.
The health care cost of drug-related morbidity and mortality in nursing facilities.
Arch Intern Med. 1997 Oct 13;157(18):2089-96.
| | • | Johnson JA, Bootman JL.
Drug-related morbidity and mortality and the economic impact of pharmaceutical care.
Am J Health Syst Pharm. 1997 Mar 1 ;54(5):554-8. No abstract available.
| | • | Cooper JW.
Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study.
J Am Geriatr Soc. 1996 Feb;44(2):194-7.
| | • | Fernandez-
Llimos F, Tuneu L, Baena MI, Garcia-Delgado A, Faus MJ.
Morbidity and mortality associated with pharmacotherapy. Evolution and current
concept of drug-related problems.
Curr Pharm Des. 2004;10(31):3947-67. PMID: 15579082 [PubMed - in process]
| | • | Javitz HS, Ward MM, Farber E, Nail L, Vallow SG.
The direct cost of care for psoriasis and psoriatic arthritis in the United States .
J Am Acad Dermatol. 2002 Jun ;46(6):850-60.
| | • | McDonnell PJ, Jacobs MR.
Hospital admissions resulting from preventable adverse drug reactions.
Ann Pharmacother. 2002 Sep;36(9):1331-6.
| | • | Anderson JG, Jay SJ, Anderson M, Hunt TJ.
Evaluating the capability of information technology to prevent adverse drug events: a computer simulation approach.
J Am Med Inform Assoc. 2002 Sep-Oct;9(5):479-90.
| | • | Gautier S, Bachelet H, Bordet R, Caron J.
The cost of adverse drug reactions.
Expert Opin Pharmacother. 2003 Mar;4(3):319-26. Review.
| | • | Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW.
Incidence and preventability of adverse drug events among older persons in the ambulatory setting.
JAMA. 2003 Mar 5;289(9):1107-16.
| | • |
Bentkover JD, Stewart EJ, Ignaszewski A, Lepage S, Liu P, Cooper J.
New technologies and potential cost savings related to morbidity and mortality
reduction in Class III/IV heart failure patients in Canada .
Int J Cardiol. 2003 Mar ;88(1):33-41.
| | • | Rodriguez-
Monguio R, Otero MJ, Rovira J.
Assessing the economic impact of adverse drug effects.
Pharmacoeconomics. 2003;21(9):623-50. Review.
| | • | Egger T, Dormann H, Ahne G, Runge U, Neubert A, Criegee-Rieck M, Gassmann KG, Brune K.
Identification of adverse drug reactions in geriatric inpatients using a computerised drug database.
Drugs Aging. 2003 ;20(10):769-76.
| | • | Pirmohamed M, Park BK.
Cytochrome P450 enzyme polymorphisms and adverse drug reactions.
Toxicology. 2003 Oct 1 ;192(1):23-32. Review.
| | • |
Curtiss FR, Fry RN, Avey SG.
Framework for pharmacy services quality improvement--a bridge to cross the quality
chasm. Part I. The opportunity and the tool.
J Manag Care Pharm. 2004 Jan-Feb;10(1):60-78. Review.
| | • | Goettler M, Schneeweiss S, Hasford J.
Adverse drug reaction monitoring--cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission.
Pharmacoepidemiol Drug Saf. 1997 Oct;6 Suppl 3:S79-90.
| | • |
Lundkvist J, Jonsson B.
Pharmacoeconomics of adverse drug reactions.
Fundam Clin Pharmacol. 2004 Jun;18(3):275-80. Review.
| | • | Dormann H, Neubert A, Criegee-Rieck M, Egger T, Radespiel-Troger M, Azaz-Livshits T, Levy M, Brune K, Hahn EG.
Readmissions and adverse drug reactions in internal medicine: the economic impact.
J Intern Med. 2004 Jun ;255(6):653-63.
| | • | Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM.
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.
BMJ. 2004 Jul 3;329(7456):15-9.
| | • | Piette JD, Heisler M, Wagner TH.
Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk.
Am J Public Health. 2004 Oct ;94(10):1782-7.
| | • | Fernandez- Llimos F, Tuneu L, Baena MI, Garcia-Delgado A, Faus MJ.
Morbidity and mortality associated with pharmacotherapy. Evolution and current concept of drug-related problems.
Curr Pharm Des. 2004;10(31):3947-67.
| | • | Pearson TF, Pittman DG, Longley JM, Grapes ZT, Vigliotti DJ, Mullis SR.
Factors associated with preventable adverse drug reactions.
Am J Hosp Pharm. 1994 Sep 15 ;51(18):2268-72.
| | • |
Gholami K, Shalviri G.
Factors associated with preventability, predictability, and severity of adverse
drug reactions.
Ann Pharmacother. 1999 Feb;33(2):236-40.
| • | Seeger JD, Kong SX, Schumock GT.
Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients.
Pharmacotherapy. 1998 Nov-Dec ;18(6):1284-9.
| | • | Temple ME, Robinson RF, Miller JC, Hayes JR, Nahata MC.
Frequency and preventability of adverse drug reactions in paediatric patients.
Drug Saf. 2004;27(11):819-29.
| | • | Johnstone DM, Kirking DM, Vinson BE.
Comparison of adverse drug reactions detected by pharmacy and medical records departments.
Am J Health Syst Pharm. 1995 Feb 1;52(3):297-301.
| | • | Gonzales-Martin G, Dominichinni H, Diaz M, Guevara A.
Adverse drug reactions (ADRs) in patients with previous history of chronic alcohol consumption without signs of chronic hepatic damage. A prospective study.
Int J Clin Pharmacol Ther. 1995 Jan;33(1):20-6.
| | • | Wu WK, Pantaleo N.
Evaluation of outpatient adverse drug reactions leading to hospitalization.
Am J Health Syst Pharm. 2003 Feb 1;60(3):253-9.
| | • | Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M.
Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies.
Br J Clin Pharmacol. 2001 Jul;52(1):77-83. Review.
| | • | Fattinger K, Roos M, Vergeres P, Holenstein C, Kind B, Masche U, Stocker DN, Braunschweig S, Kullak-Ublick GA, Galeazzi RL, Follath F, Gasser T, Meier PJ.
Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine.
Br J Clin Pharmacol. 2000 Feb;49(2):158-67.
| | • | Winterstein AG, Hatton RC, Gonzalez- Rothi R, Johns TE, Segal R.
Identifying clinically significant preventable adverse drug events through a hospital's database of adverse drug reaction reports.
Am J Health Syst Pharm. 2002 Sep 15;59(18):1742-9.
| | • | Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER.
Clinical and economic impact of adverse drug reactions in hospitalized patients.
Ann Pharmacother. 2000 Dec;34(12):1373-9.
| | • | Olivier P, Boulbes O, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M.
Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department.
Drug Saf. 2002;25(14):1035-44.
| | • | Letrilliart L, Hanslik T, Biour M, Fagot JP, Guiguet M, Flahault A.
Postdischarge adverse drug reactions in primary care originating from hospital care in France: a nationwide prospective study.
Drug Saf. 2001;24(10):781-92.
| | • | Huic M, Mucolic V, Vrhovac B, Francetic I, Bakran I, Giljanovic S.
Adverse drug reactions resulting in hospital admission.
Int J Clin Pharmacol Ther. 1994 Dec;32(12):675-82.
| | • | Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL.
Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units.
Crit Care Med. 1997 Aug ;25(8):1289-97.
| | • | Weiss J, Krebs S, Hoffmann C, Werner U, Neubert A, Brune K, Rascher W.
Survey of adverse drug reactions on a pediatric ward: a strategy for early and detailed detection.
Pediatrics. 2002 Aug;110(2 Pt 1):254-7.
| | • | Bowman L, Carlstedt BC, Black CD.
Incidence of adverse drug reactions in adult medical inpatients.
Can J Hosp Pharm. 1994 Oct ;47(5):209-16.
| | • | Ryan M, Gora-Harper ML, Caldwell F.
Experience with an adverse drug reaction reporting program in a neurology specialty clinic.
Ann Pharmacother. 2002 Feb;36(2):231-5.
| | • | Dormann H, Criegee-Rieck M, Neubert A, Egger T, Geise A, Krebs S, Schneider T, Levy M, Hahn E, Brune K.
Lack of awareness of community-acquired adverse drug reactions upon hospital admission : dimensions and consequences of a dilemma.
Drug Saf. 2003;26(5):353-62.
| | • | Onder G, Pedone C, Landi F, Cesari M, Della Vedova C, Bernabei R, Gambassi G.
Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA).
J Am Geriatr Soc. 2002 Dec ;50(12):1962-8.
| | • | Chrischilles EA, Segar ET, Wallace RB.
Self-reported adverse drug reactions and related resource use. A study of community-dwelling persons 65 years of age and older.
Ann Intern Med. 1992 Oct 15 ;117(8):634-40.
| | • | Gurwitz JH, Field TS, Avorn J, McCormick D, Jain S, Eckler M, Benser M, Edmondson AC, Bates DW.
Incidence and preventability of adverse drug events in nursing homes.
Am J Med. 2000 Aug 1;109(2):87-94.
| | • | Tschepik W, Segal R, Sherrin TP, Schneider DN, Hammond RL.
Therapeutic risk-assessment model for identifying patients with adverse drug reactions.
Am J Hosp Pharm. 1990 Feb ;47(2):330-4.
| | • | Schneider JK, Mion LC, Frengley JD.
Adverse drug reactions in an elderly outpatient population.
Am J Hosp Pharm. 1992 Jan ;49(1):90-6.
| | • | Veehof LJ, Stewart RE, Meyboom-de Jong B, Haaijer-Ruskamp FM.
Adverse drug reactions and polypharmacy in the elderly in general practice.
Eur J Clin Pharmacol. 1999 Sep;55(7):533-6.
| | • | Green CF, Mottram DR, Rowe PH, Pirmohamed M.
Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study.
J Clin Pharm Ther. 2000 Oct;25(5):355-61.
| | • | van Grootheest K, van Puijenbroek EP, de Jong-van den Berg LT.
Do pharmacists' reports of adverse drug reactions reflect patients' concerns?
Pharm World Sci. 2004 Jun ;26(3):155-9.
| | • | Cutroneo P, Greco S, Cucinotta G, Arcoraci V, Caputi AP.
Spontaneous reporting of adverse drug reactions in elderly patients in Sicily (Italy).
Pharmacol Res. 1999 Jul;40(1):41-6.
| | • | Hallas J.
Drug related hospital admissions in subspecialities of internal medicine.
Dan Med Bull. 1996 Apr;43(2):141-55. Review.
| | • | Ajayi FO, Sun H, Perry J.
Adverse drug reactions: a review of relevant factors.
J Clin Pharmacol. 2000 Oct;40(10):1093-101. Review.
| | • | Marcellino K, Kelly WN.
Potential risks and prevention, Part 3: Drug-induced threats to life.
Am J Health Syst Pharm. 2001 Aug 1;58(15):1399-405. Review.
| | • | Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E.
Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies.
Br J Clin Pharmacol. 1998 May;45(5):496-500.
| | • | Benjamin DM, Pendrak RF.
Medication errors: an analysis comparing PHICO's closed claims data and PHICO's Event Reporting Trending System (PERTS).
J Clin Pharmacol. 2003 Jul;43(7):754-9.
| |
|
